Tagged Articles

lower-limb amputation 1 articles

Europe requires lower limb amputation risk be added to Invokana safety label

European drug regulators have determined that new warnings regarding lower limb amputations should be added to the safety labels of type 2 diabetes drugs known as SGLT2 inhibitors. The warning is based on a European Medicine Agency (EMA) review of data from two ongoing clinical trials on SGLT2 inhibitors containing the active ingredient canagliflozin, which includes the brand name drugs Invokana and Invokamet (which sells under the name Vokanamet in Europe). One of the clinical trials is to determine canagliflozin’s impact on patients at high risk for cardiovascular events and the other is to assess affects on the kidneys. In ... Read More